Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-523: Lenvatinib plus Pembrolizumab in Selected Solid Tumors
NCT03006887Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib and pembrolizumab in non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), endometrial carcinoma and 3 more, sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events and Number of Participants With Dose-limiting Toxicities. Started Jan 2017; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)endometrial carcinomaurothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03006887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006887.